Literature DB >> 23975178

Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression.

Zyrafete Kuçi1, Julia Seiberth, Hatixhe Latifi-Pupovci, Sibylle Wehner, Stefan Stein, Manuel Grez, Halvard Bönig, Ulrike Köhl, Thomas Klingebiel, Peter Bader, Selim Kuçi.   

Abstract

Previous reports demonstrated a relationship between proliferation potential and trilineage differentiation in mesenchymal stromal cell-derived clones generated using plastic adherence (PA-MSCs). However, there are no reports presenting a clonal analysis of the proliferative potential, differentiation potential and allosuppressive effects of human mesenchymal stromal cell subsets. In this study, we performed a clonal analysis of mesenchymal stromal cells generated from human CD271(+) bone marrow mononuclear cells (CD271-MSCs). After transfection with the gene encoding green fluorescent protein, the cells were single-cell sorted and cultured for 2-4 weeks. A population doubling analysis demonstrated that 25% of CD271-MSC clones are fast-proliferating clones compared to only 10% of PA-MSC clones. Evaluation of the allosuppressive potential demonstrated that 81.8% of CD271-MSC clones were highly allosuppressive compared to only 58% of PA-MSC clones. However, no consistent correlation was observed between allosuppression and proliferative potential. Prostaglandin E2 levels were positively correlated with the allosuppressive activity of individual clones, suggesting that this molecule may be a useful predictive biomarker for the allosuppressive potential of mesenchymal stromal cells. In contrast, inhibitory studies of indoleamine 2,3 dioxygenase indicated that none of the clones used this enzyme to mediate their allosuppressive effect. Differentiation studies revealed the presence of tripotent, bipotent and unipotent CD271-MSC and PA-MSC clones which suppressed the allogeneic reaction to differing extents in vitro. In conclusion, our findings demonstrate differences between CD271-MSCs and PA-MSCs and indicate that neither proliferation potential nor differentiation potential represents a consistent predictive parameter for the immunomodulatory effects of either type of mesenchymal stromal cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23975178      PMCID: PMC3789467          DOI: 10.3324/haematol.2013.092700

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  32 in total

1.  Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells.

Authors:  Takeshi Okamoto; Tomoki Aoyama; Tomitaka Nakayama; Takeharu Nakamata; Taisuke Hosaka; Koichi Nishijo; Takashi Nakamura; Tohru Kiyono; Junya Toguchida
Journal:  Biochem Biophys Res Commun       Date:  2002-07-12       Impact factor: 3.575

2.  Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens.

Authors:  Julius A Potian; Hana Aviv; Nicholas M Ponzio; Jonathan S Harrison; Pranela Rameshwar
Journal:  J Immunol       Date:  2003-10-01       Impact factor: 5.422

3.  Clonal analysis of the differentiation potential of human adipose-derived adult stem cells.

Authors:  Farshid Guilak; Kristen E Lott; Hani A Awad; Qiongfang Cao; Kevin C Hicok; Beverley Fermor; Jeffrey M Gimble
Journal:  J Cell Physiol       Date:  2006-01       Impact factor: 6.384

4.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.

Authors:  Massimo Di Nicola; Carmelo Carlo-Stella; Michele Magni; Marco Milanesi; Paolo D Longoni; Paola Matteucci; Salvatore Grisanti; Alessandro M Gianni
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

5.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

6.  Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness.

Authors:  Shaul Beyth; Zipora Borovsky; Dror Mevorach; Meir Liebergall; Zulma Gazit; Hadi Aslan; Eithan Galun; Jacob Rachmilewitz
Journal:  Blood       Date:  2004-10-28       Impact factor: 22.113

7.  Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes.

Authors:  K Le Blanc; I Rasmusson; C Götherström; C Seidel; B Sundberg; M Sundin; K Rosendahl; C Tammik; O Ringdén
Journal:  Scand J Immunol       Date:  2004-09       Impact factor: 3.487

8.  Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.

Authors:  Roland Meisel; Andree Zibert; Maurice Laryea; Ulrich Göbel; Walter Däubener; Dagmar Dilloo
Journal:  Blood       Date:  2004-03-04       Impact factor: 22.113

9.  Mesenchymal stem cells can be differentiated into endothelial cells in vitro.

Authors:  Joachim Oswald; Sabine Boxberger; Birgitte Jørgensen; Silvia Feldmann; Gerhard Ehninger; Martin Bornhäuser; Carsten Werner
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

10.  Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model.

Authors:  A Muraglia; R Cancedda; R Quarto
Journal:  J Cell Sci       Date:  2000-04       Impact factor: 5.285

View more
  23 in total

Review 1.  [Mesenchymal stem/stroma cells : Therapeutic potential in the treatment of autoimmune diseases].

Authors:  R Schäfer; T Daikeler
Journal:  Z Rheumatol       Date:  2016-10       Impact factor: 1.372

2.  Orthogonal potency analysis of mesenchymal stromal cell function during ex vivo expansion.

Authors:  Danika Khong; Matthew Li; Amy Singleton; Ling-Yee Chin; Shilpaa Mukundan; Biju Parekkadan
Journal:  Exp Cell Res       Date:  2017-11-11       Impact factor: 3.905

3.  Mechanisms of Immune Suppression Utilized by Canine Adipose and Bone Marrow-Derived Mesenchymal Stem Cells.

Authors:  Lyndah Chow; Valerie Johnson; Jonathan Coy; Dan Regan; Steven Dow
Journal:  Stem Cells Dev       Date:  2017-01-24       Impact factor: 3.272

4.  Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation.

Authors:  Jeffery J Auletta; Saada K Eid; Patiwet Wuttisarnwattana; Ines Silva; Leland Metheny; Matthew D Keller; Rocio Guardia-Wolff; Chen Liu; Fangjing Wang; Theodore Bowen; Zhenghong Lee; Luis A Solchaga; Sudipto Ganguly; Megan Tyler; David L Wilson; Kenneth R Cooke
Journal:  Stem Cells       Date:  2015-02       Impact factor: 6.277

5.  Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.

Authors:  Zyrafete Kuçi; Halvard Bönig; Hermann Kreyenberg; Milica Bunos; Anna Jauch; Johannes W G Janssen; Marijana Škifić; Kristina Michel; Ben Eising; Giovanna Lucchini; Shahrzad Bakhtiar; Johann Greil; Peter Lang; Oliver Basu; Irene von Luettichau; Ansgar Schulz; Karl-Walter Sykora; Andrea Jarisch; Jan Soerensen; Emilia Salzmann-Manrique; Erhard Seifried; Thomas Klingebiel; Peter Bader; Selim Kuçi
Journal:  Haematologica       Date:  2016-05-12       Impact factor: 9.941

6.  p75 neurotrophin receptor regulates differential mineralization of rat ectomesenchymal stem cells.

Authors:  Kun Yang; Yingying Wang; Yingxin Ju; Gang Li; Chang Liu; Junyu Liu; Qi Liu; Xiujie Wen; Lu Chuan Liu
Journal:  Cell Prolif       Date:  2016-09-27       Impact factor: 6.831

7.  Potential Effect of CD271 on Human Mesenchymal Stromal Cell Proliferation and Differentiation.

Authors:  Giovanna Calabrese; Raffaella Giuffrida; Debora Lo Furno; Nunziatina Laura Parrinello; Stefano Forte; Rosario Gulino; Cristina Colarossi; Luciana Rita Schinocca; Rosario Giuffrida; Venera Cardile; Lorenzo Memeo
Journal:  Int J Mol Sci       Date:  2015-07-09       Impact factor: 5.923

8.  Mesenchymal stem cells derived from human induced pluripotent stem cells retain adequate osteogenicity and chondrogenicity but less adipogenicity.

Authors:  Ran Kang; Yan Zhou; Shuang Tan; Guangqian Zhou; Lars Aagaard; Lin Xie; Cody Bünger; Lars Bolund; Yonglun Luo
Journal:  Stem Cell Res Ther       Date:  2015-08-18       Impact factor: 6.832

Review 9.  Wharton's Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease.

Authors:  Joseph P McGuirk; J Robert Smith; Clint L Divine; Micheal Zuniga; Mark L Weiss
Journal:  Pharmaceuticals (Basel)       Date:  2015-04-16

10.  Ex vivo identification and characterization of a population of CD13(high) CD105(+) CD45(-) mesenchymal stem cells in human bone marrow.

Authors:  Carmen Muñiz; Cristina Teodosio; Andrea Mayado; Ana Teresa Amaral; Sergio Matarraz; Paloma Bárcena; Maria Luz Sanchez; Iván Alvarez-Twose; María Diez-Campelo; Andrés C García-Montero; Juan F Blanco; Maria Consuelo Del Cañizo; Javier del Pino Montes; Alberto Orfao
Journal:  Stem Cell Res Ther       Date:  2015-09-07       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.